Cargando…
Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations
The recent interest in advanced biologic therapies in veterinary medicine has opened up opportunities for new treatment modalities with considerable clinical potential. Studies with mesenchymal stromal cells (MSCs) from animal species have focused on in vitro characterization (mostly following proto...
Autores principales: | , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230578/ https://www.ncbi.nlm.nih.gov/pubmed/35754551 http://dx.doi.org/10.3389/fvets.2022.897150 |
_version_ | 1784735095471472640 |
---|---|
author | Ivanovska, Ana Wang, Mengyu Arshaghi, Tarlan Eslami Shaw, Georgina Alves, Joel Byrne, Andrew Butterworth, Steven Chandler, Russell Cuddy, Laura Dunne, James Guerin, Shane Harry, Rob McAlindan, Aidan Mullins, Ronan A. Barry, Frank |
author_facet | Ivanovska, Ana Wang, Mengyu Arshaghi, Tarlan Eslami Shaw, Georgina Alves, Joel Byrne, Andrew Butterworth, Steven Chandler, Russell Cuddy, Laura Dunne, James Guerin, Shane Harry, Rob McAlindan, Aidan Mullins, Ronan A. Barry, Frank |
author_sort | Ivanovska, Ana |
collection | PubMed |
description | The recent interest in advanced biologic therapies in veterinary medicine has opened up opportunities for new treatment modalities with considerable clinical potential. Studies with mesenchymal stromal cells (MSCs) from animal species have focused on in vitro characterization (mostly following protocols developed for human application), experimental testing in controlled studies and clinical use in veterinary patients. The ability of MSCs to interact with the inflammatory environment through immunomodulatory and paracrine mechanisms makes them a good candidate for treatment of inflammatory musculoskeletal conditions in canine species. Analysis of existing data shows promising results in the treatment of canine hip dysplasia, osteoarthritis and rupture of the cranial cruciate ligament in both sport and companion animals. Despite the absence of clear regulatory frameworks for veterinary advanced therapy medicinal products, there has been an increase in the number of commercial cell-based products that are available for clinical applications, and currently the commercial use of veterinary MSC products has outpaced basic research on characterization of the cell product. In the absence of quality standards for MSCs for use in canine patients, their safety, clinical efficacy and production standards are uncertain, leading to a risk of poor product consistency. To deliver high-quality MSC products for veterinary use in the future, there are critical issues that need to be addressed. By translating standards and strategies applied in human MSC manufacturing to products for veterinary use, in a collaborative effort between stem cell scientists and veterinary researchers and surgeons, we hope to facilitate the development of quality standards. We point out critical issues that need to be addressed, including a much higher level of attention to cell characterization, manufacturing standards and release criteria. We provide a set of recommendations that will contribute to the standardization of cell manufacturing methods and better quality assurance. |
format | Online Article Text |
id | pubmed-9230578 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | Frontiers Media S.A. |
record_format | MEDLINE/PubMed |
spelling | pubmed-92305782022-06-25 Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations Ivanovska, Ana Wang, Mengyu Arshaghi, Tarlan Eslami Shaw, Georgina Alves, Joel Byrne, Andrew Butterworth, Steven Chandler, Russell Cuddy, Laura Dunne, James Guerin, Shane Harry, Rob McAlindan, Aidan Mullins, Ronan A. Barry, Frank Front Vet Sci Veterinary Science The recent interest in advanced biologic therapies in veterinary medicine has opened up opportunities for new treatment modalities with considerable clinical potential. Studies with mesenchymal stromal cells (MSCs) from animal species have focused on in vitro characterization (mostly following protocols developed for human application), experimental testing in controlled studies and clinical use in veterinary patients. The ability of MSCs to interact with the inflammatory environment through immunomodulatory and paracrine mechanisms makes them a good candidate for treatment of inflammatory musculoskeletal conditions in canine species. Analysis of existing data shows promising results in the treatment of canine hip dysplasia, osteoarthritis and rupture of the cranial cruciate ligament in both sport and companion animals. Despite the absence of clear regulatory frameworks for veterinary advanced therapy medicinal products, there has been an increase in the number of commercial cell-based products that are available for clinical applications, and currently the commercial use of veterinary MSC products has outpaced basic research on characterization of the cell product. In the absence of quality standards for MSCs for use in canine patients, their safety, clinical efficacy and production standards are uncertain, leading to a risk of poor product consistency. To deliver high-quality MSC products for veterinary use in the future, there are critical issues that need to be addressed. By translating standards and strategies applied in human MSC manufacturing to products for veterinary use, in a collaborative effort between stem cell scientists and veterinary researchers and surgeons, we hope to facilitate the development of quality standards. We point out critical issues that need to be addressed, including a much higher level of attention to cell characterization, manufacturing standards and release criteria. We provide a set of recommendations that will contribute to the standardization of cell manufacturing methods and better quality assurance. Frontiers Media S.A. 2022-06-10 /pmc/articles/PMC9230578/ /pubmed/35754551 http://dx.doi.org/10.3389/fvets.2022.897150 Text en Copyright © 2022 Ivanovska, Wang, Arshaghi, Shaw, Alves, Byrne, Butterworth, Chandler, Cuddy, Dunne, Guerin, Harry, McAlindan, Mullins and Barry. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms. |
spellingShingle | Veterinary Science Ivanovska, Ana Wang, Mengyu Arshaghi, Tarlan Eslami Shaw, Georgina Alves, Joel Byrne, Andrew Butterworth, Steven Chandler, Russell Cuddy, Laura Dunne, James Guerin, Shane Harry, Rob McAlindan, Aidan Mullins, Ronan A. Barry, Frank Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations |
title | Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations |
title_full | Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations |
title_fullStr | Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations |
title_full_unstemmed | Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations |
title_short | Manufacturing Mesenchymal Stromal Cells for the Treatment of Osteoarthritis in Canine Patients: Challenges and Recommendations |
title_sort | manufacturing mesenchymal stromal cells for the treatment of osteoarthritis in canine patients: challenges and recommendations |
topic | Veterinary Science |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9230578/ https://www.ncbi.nlm.nih.gov/pubmed/35754551 http://dx.doi.org/10.3389/fvets.2022.897150 |
work_keys_str_mv | AT ivanovskaana manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT wangmengyu manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT arshaghitarlaneslami manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT shawgeorgina manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT alvesjoel manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT byrneandrew manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT butterworthsteven manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT chandlerrussell manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT cuddylaura manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT dunnejames manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT guerinshane manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT harryrob manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT mcalindanaidan manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT mullinsronana manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations AT barryfrank manufacturingmesenchymalstromalcellsforthetreatmentofosteoarthritisincaninepatientschallengesandrecommendations |